The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus

Published:2022-03-21 Issue:1 Volume:25 Page:393-402
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Pollock Richard F.¹^ORCID,Norrbacka Kirsi²,Boye Kristina S.³,Osumili Beatrice⁴^ORCID,Valentine William J.⁵

Affiliation:

1. Health Economics and Outcomes Research, Covalence Research Ltd, London, UK

2. Eli Lilly Finland, Helsinki, Finland

3. Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, USA

4. GPORWE International, Eli Lilly and Company Ltd, Surrey, UK

5. Health Economics, Ossian Health Economics and Communications, Basel, Switzerland

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2035132

Reference50 articles.

1. World Health Organization. Health Topics – Diabetes; [cited 2020 Nov 27]. Available from: https://www.who.int/health-topics/diabetes#tab=tab_1.

2. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends

3. Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030

4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

5. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting;Primary Care Diabetes;2024-07

2. Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective;PharmacoEconomics;2024-05-08

3. Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling;PharmacoEconomics;2024-03-18

4. The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review;Diabetes Technology & Therapeutics;2024-03-01

5. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States;Journal of Managed Care & Specialty Pharmacy;2024-02-03